DMD treatment SMT-01, a cell replacement therapy, received FDA orphan drug and rare pediatric disease designations.
Sarepta's Elevidys approval, revenue growth projections, and competitive position make it a strong investment in DMD ...
Age-related musculoskeletal diseases are a significant public health concern that critically impacts the motor functions and the quality of life in the elderly. The musculoskeletal system supports the ...
Six-year-old Cooper Wood was diagnosed with Duchenne muscular dystrophy earlier this year. When his parents applied for a one ...
Satellos Bioscience Inc. ("Satellos" or the "Company") , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, ...
Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, ...
AI-driven biotech Somite.ai scores dual FDA designations for its novel treatment, potentially fast-tracking hope for families ...
The FDA has granted Orphan Drug and Rare Pediatric Disease Designations to Somite’s cell replacement therapy for the ...
The Healthy on MSN3d
Here’s What Happens If You Don’t Brush Your Teeth, According to a DentistOne dentist explains, 'Your mouth houses 700 species of microbes.' While not all of these are harmful, failing to brush your ...
GlobalData on MSN4d
Duchenne muscular dystrophy: major trials and events to watch in 2023A possible gene therapy approval and a series of major trials readouts set the stage for a busy year of drug development in Duchenne muscular dystrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback